

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CanSino Biologics Inc.
康希諾生物股份公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 6185)

CHANGE OF EMPLOYEE REPRESENTATIVE SUPERVISOR

RESIGNATION OF EMPLOYEE REPRESENTATIVE SUPERVISOR

The board of directors (the “**Board**”) of CanSino Biologics Inc. (the “**Company**”) announces that Ms. Zhengfang LIAO (“**Ms. LIAO**”) ceased to serve as an employee representative supervisor of the second session of the board of supervisors of the Company (the “**Board of Supervisors**”) due to personal reasons with effect from March 2, 2023. Ms. LIAO will continue to hold other positions in the Company after the resignation.

Ms. LIAO has confirmed that she has no disagreement with the Board or the Board of Supervisors and there are no other matters relating to her resignation that need to be brought to the attention of the shareholders of the Company or The Stock Exchange of Hong Kong Limited.

The Board and the Board of Supervisors expressed their gratitude to Ms. LIAO for her contribution to the development of the Company during her tenure as an employee representative supervisor of the Company.

APPOINTMENT OF EMPLOYEE REPRESENTATIVE SUPERVISOR

The Board is also pleased to announce that the Company convened an employee representative meeting on March 3, 2023, during which Ms. Yuan ZHOU (“**Ms. ZHOU**”) was elected as an employee representative supervisor of the Board of Supervisors. Ms. ZHOU’s term of office commences from the date of the resolution of the employee representative meeting until the expiry date of the second session of the Board of Supervisors.

The biographical details of Ms. ZHOU are set out below:

Ms. ZHOU, female, born in 1988, Chinese nationality, with no permanent residency outside China, Master of Laws, worked as a legal assistant in Grandall Law Firm (Tianjin) (國浩(天津)律師事務所) from October 2012 to July 2016. From August 2016 to April 2019, she worked as a legal manager in Herong Futures Co., Ltd. (和融期貨有限責任公司). Since May 2019, she has served successively as legal manager, senior legal manager, deputy legal director and senior director of the legal and compliance department and internal audit department of the Company. She is currently serving as a supervisor in certain subsidiaries of the Company, namely CanSino SPH Biologics Inc., CanSino Biology (Shanghai) Co., Ltd., CanSino (Shanghai) Biotechnology Co., Ltd., CanSino (Shanghai) Biological Research and Development Co., Ltd., Kangbo (Tianjin) Pharmaceutical Technology Co., Ltd. and Bomai (Tianjin) Venture Capital Management Co., Ltd.

Ms. ZHOU has entered into a service contract with the Company. Ms. ZHOU will not receive additional remuneration from the Company to act as an employee representative supervisor of the Company.

Saved as disclosed above, as at the date of this announcement, Ms. ZHOU has confirmed that she (i) does not hold any other positions in the Company or its subsidiaries; (ii) does not have any relationship with any directors, supervisors, senior management or substantial or controlling shareholders of the Company; and (iii) has not held any directorship or supervisor positions in any listed companies in the past three years. As at the date of this announcement, Ms. ZHOU does not have any interest in any shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Saved as disclosed above, as at the date of this announcement, there is no other information in respect of Ms. ZHOU that needs to be disclosed pursuant to Rule 13.51(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, and there is no other matter in respect of her appointment that needs to be brought to the attention of the shareholders of the Company.

By order of the Board
CanSino Biologics Inc.
Xuefeng YU
Chairman

Hong Kong, March 3, 2023

As of the date of this announcement, the Board comprises Dr. Xuefeng YU, Dr. Shou Bai CHAO, Dr. Tao ZHU, Dr. Dongxu QIU and Ms. Jing WANG as executive directors, Mr. Liang LIN, Ms. Nisa Bernice Wing-Yu LEUNG and Mr. Zhi XIAO as non-executive directors, and Mr. Shiu Kwan Danny WAI, Ms. Zhu XIN, Mr. Shuifa GUI and Mr. Jianzhong LIU as independent non-executive directors.